Rituximab Medical Necessity Criteria
Defines medical necessity criteria, prior authorization requirements, preferred status of rituximab products, covered indications (selected FDA and off-label autoimmune, hematologic, vasculitic, transplant-related conditions) and investigational exclusions for non-oncologic uses for BCBSMA commercial members. Applies to outpatient medical and pharmacy benefits per formulary/prior authorization table.
Removed rituximab from the Cotivity program.
Updated to require dose and frequency for the policy to coincide with the Medical claim edits.
Updated policy to make Truxima preferred and Riabni non-preferred.
Reformatted policy.
Updated policy to make Riabni preferred and Truxima non-preferred.
BCBSA National medical policy review; no changes to policy statements, new references added.
New medical policy describing medically necessary and investigational indications.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.